Published in J Immunol on March 09, 2016
HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells. Cell Host Microbe (2017) 0.80
Deciphering the KIR system at super-resolution for NK and T cell biology. Immunology (2016) 0.79
KIR3DL1/ HL A-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. J Clin Oncol (2017) 0.76
Natural Killer Cell Diversity in Viral Infection: Why and How Much? Pathog Immun (2016) 0.76
Sequence and Phylogenetic Analysis of the Untranslated Promoter Regions for HLA Class I Genes. J Immunol (2017) 0.75
Assessment of the antiviral capacity of primary natural killer cells by optimized in vitro quantification of HIV-1 replication. J Immunol Methods (2016) 0.75
HIV-1 Control by NK Cells via Reduced Interaction between KIR2DL2 and HLA-C(∗)12:02/C(∗)14:03. Cell Rep (2016) 0.75
Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections? Front Immunol (2017) 0.75
Killer Immunoglobulin-Like Receptor Allele Determination Using Next-Generation Sequencing Technology. Front Immunol (2017) 0.75
KIR3DL01 upregulation on gut natural killer cells in response to SIV infection of KIR- and MHC class I-defined rhesus macaques. PLoS Pathog (2017) 0.75
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet (2002) 7.58
Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature (2005) 7.40
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity (1999) 6.80
Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 6.73
A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood (2005) 4.64
Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med (2007) 4.14
Self-tolerance of natural killer cells. Nat Rev Immunol (2006) 3.75
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med (2006) 3.50
The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med (1995) 3.43
Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol (2013) 3.38
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 3.07
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest (2012) 3.00
Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol (2008) 2.76
MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood (2008) 2.71
'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. Nat Immunol (2010) 2.57
Global diversity and evidence for coevolution of KIR and HLA. Nat Genet (2007) 2.40
Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat Genet (2007) 2.36
HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A (2008) 2.31
The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood (2008) 2.24
Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol (2007) 2.12
NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol (2009) 2.12
KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol (2005) 2.07
Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol (2001) 2.02
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol (1991) 2.00
Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature (2011) 1.94
Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol (2007) 1.94
HIV and HLA class I: an evolving relationship. Immunity (2012) 1.91
The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol (2003) 1.89
How do natural killer cells find self to achieve tolerance? Immunity (2006) 1.74
Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol (1990) 1.68
Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum (2002) 1.56
KIR-HLA intercourse in HIV disease. Trends Microbiol (2008) 1.55
Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. Eur J Immunol (2003) 1.53
Inhibitory KIR/HLA incompatibility between sexual partners confers protection against HIV-1 transmission. Blood (2012) 1.49
A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS (2008) 1.47
Inhibitory Killer Immunoglobulin-like Receptors to self HLA-B and HLA-C ligands contribute differentially to Natural Killer cell functional potential in HIV infected slow progressors. Clin Immunol (2012) 1.47
Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. Eur J Immunol (2007) 1.35
Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance. Sci Signal (2011) 1.30
Inhibitory signaling blocks activating receptor clustering and induces cytoskeletal retraction in natural killer cells. J Cell Biol (2011) 1.26
Effects of MHC class I alleles on licensing of Ly49A+ NK cells. J Immunol (2010) 1.24
Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants. J Immunol (1990) 1.19
Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3. J Immunol (2012) 1.19
Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57. J Virol (2011) 1.14
Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? J Immunol (2008) 1.13
Skewing of the NK cell repertoire by MHC class I via quantitatively controlled enrichment and contraction of specific Ly49 subsets. J Immunol (2012) 1.11
Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant (2008) 1.10
Innate immune control of HIV. Cold Spring Harb Perspect Med (2012) 1.09
Co-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan Africans. PLoS Genet (2013) 1.08
HIV protective KIR3DL1/S1-HLA-B genotypes influence NK cell-mediated inhibition of HIV replication in autologous CD4 targets. PLoS Pathog (2014) 1.03
Allele-level haplotype frequencies and pairwise linkage disequilibrium for 14 KIR loci in 506 European-American individuals. PLoS One (2012) 1.02
Immunogenetics of killer cell immunoglobulin-like receptors. Mol Immunol (2005) 0.99
Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice. PLoS One (2010) 0.96
Interactions of NK cell receptor KIR3DL1*004 with chaperones and conformation-specific antibody reveal a functional folded state as well as predominant intracellular retention. J Immunol (2010) 0.95
Mutational and structural analysis of KIR3DL1 reveals a lineage-defining allotypic dimorphism that impacts both HLA and peptide sensitivity. J Immunol (2014) 0.94
Cutting edge: NK cell licensing modulates adhesion to target cells. J Immunol (2013) 0.93
KIR3DS1/L1 and HLA-Bw4-80I are associated with HIV disease progression among HIV typical progressors and long-term nonprogressors. BMC Infect Dis (2013) 0.92
Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1. J Virol (2015) 0.92
Polymorphic HLA-C Receptors Balance the Functional Characteristics of KIR Haplotypes. J Immunol (2015) 0.91
Preparation and use of HIV-1 infected primary CD4+ T-cells as target cells in natural killer cell cytotoxic assays. J Vis Exp (2011) 0.89
Development of a novel multiplex PCR assay to detect functional subtypes of KIR3DL1 alleles. PLoS One (2014) 0.88
Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells. BMC Biotechnol (2013) 0.82
The production of KIR-Fc fusion proteins and their use in a multiplex HLA class I binding assay. J Immunol Methods (2015) 0.82
KIR3DL1 genetic diversity and phenotypic variation in the Chinese Han population. Genes Immun (2013) 0.81
KIR-HLA-A and B alleles of the Bw4 epitope against HIV infection in discordant heterosexual couples in Chaco Argentina. Immunology (2013) 0.81
KIR3DS1-Specific D0 Domain Polymorphisms Disrupt KIR3DL1 Surface Expression and HLA Binding. J Immunol (2015) 0.80
HSV-2 specifically down regulates HLA-C expression to render HSV-2-infected DCs susceptible to NK cell killing. PLoS Pathog (2013) 0.78
Donor activating KIR2DS1 in leukemia. N Engl J Med (2014) 0.77